軒竹生物(02575.HK)安奈拉唑鈉腸溶片獲國家藥監局受理RE新適應症申請

阿斯達克財經

06/30

軒竹生物(02575.HK) 公布，公司自主研發的國家1類創新藥安奈拉唑鈉腸溶片(商品名：安久衛)用於治療成人反流性食管炎(RE)的新適應症上市申請於近日獲國家藥品監督管理局正式受理。RE適應症是安奈拉唑鈉繼十二指腸潰瘍後第二個遞交上市申請的適應症。(sl/a)(港股報價延遲最少十五分鐘。沽空資料截至 2026-06-29 16:25。)AASTOCKS新聞

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2647311584"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2647311584\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2647311584?lang=zh_TW&edition=fundamental","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20251024110439490_s.jpg","is_english":false,"pubTime":"2026-06-30 12:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2647311584","market":"other","top_or_hot":-1,"title":"軒竹生物(02575.HK)安奈拉唑鈉腸溶片獲國家藥監局受理RE新適應症申請","media":"阿斯達克財經","content":"<div>\n<p>軒竹生物(02575.HK) 公布，公司自主研發的國家1類創新藥安奈拉唑鈉腸溶片(商品名：安久衛)用於治療成人反流性食管炎(RE)的新適應症上市申請於近日獲國家藥品監督管理局正式受理。RE適應症是安奈拉唑鈉繼十二指腸潰瘍後第二個遞交上市申請的適應症。(sl/a)(港股報價延遲最少十五分鐘。沽空資料截至 2026-06-29 16:25。)AASTOCKS新聞</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1531238/latest-news/AAFN\">網頁鏈接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>軒竹生物(02575.HK)安奈拉唑鈉腸溶片獲國家藥監局受理RE新適應症申請</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n軒竹生物(02575.HK)安奈拉唑鈉腸溶片獲國家藥監局受理RE新適應症申請\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">阿斯達克財經</strong><span class=\"h-time small\">2026-06-30 12:16</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>軒竹生物(02575.HK) 公布，公司自主研發的國家1類創新藥安奈拉唑鈉腸溶片(商品名：安久衛)用於治療成人反流性食管炎(RE)的新適應症上市申請於近日獲國家藥品監督管理局正式受理。RE適應症是安奈拉唑鈉繼十二指腸潰瘍後第二個遞交上市申請的適應症。(sl/a)(港股報價延遲最少十五分鐘。沽空資料截至 2026-06-29 16:25。)AASTOCKS新聞</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1531238/latest-news/AAFN\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1531238/latest-news/AAFN\">阿斯達克財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02575","symbol_name":"軒竹生物-B","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1531238/latest-news/AAFN","article_id":"2647311584","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20251024110439490_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1531238/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2647311584","pubTimestamp":1782792960,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"軒竹生物(02575.HK) 公布，公司自主研發的國家1類創新藥安奈拉唑鈉腸溶片(商品名：安久衞)用於治療成人反流性食管炎(RE)的新適應症上市申請於近日獲國家藥品監督管理局正式受理。RE適應症是安奈拉唑鈉繼十二指腸潰瘍後第二個遞交上市申請的適應症。(sl/a)(港股報價延遲最少十五分鐘。沽空資料截至 2026-06-29 16:25。)AASTOCKS新聞","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02575":"轩竹生物-B","BK1191":"制药"},"translate_title":"Xuanzhu Biotech (02575.HK) aneprazole sodium enteric-coated tablets were accepted by the State Food and Drug Administration for RE new indication application","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02575":1.5},"content_text":"軒竹生物(02575.HK) 公布，公司自主研發的國家1類創新藥安奈拉唑鈉腸溶片(商品名：安久衞)用於治療成人反流性食管炎(RE)的新適應症上市申請於近日獲國家藥品監督管理局正式受理。RE適應症是安奈拉唑鈉繼十二指腸潰瘍後第二個遞交上市申請的適應症。(sl/a)(港股報價延遲最少十五分鐘。沽空資料截至 2026-06-29 16:25。)AASTOCKS新聞","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}